What is Sovihep and what is it used for? SoviHep - Zydus indian sofosbuvir contains the active substance sofosbuvir, a HCV-like NS5B inhibitor that is used to treat hepatitis C virus infection in adults aged 18 years and older. Sofosbuvir should always be taken with other antiviral medicines. This medicine has no effect on its own. It is taken in treatment schedules prescribed by the hepatologist together with: - ledipasvir - ribavirin - daclatasvir It is very important to read the prospectuses for the other medicines you are taking with Sofosbuvir. If you have any further questions about your medication, ask your doctor. 2. What do you need to know before you take Sovihep? Do not take Sofosbuvir if you are allergic to sofosbuvir or any of the other ingredients of this medicine If this is the case with you, talk to your doctor immediately. Warnings and precautions Sofosbuvir should always be taken with other medicines according to the treatment schedule established by your doctor.
WHAT DO YOU MEAN BY SOVIHEP V TABLETS ?
SoviHep V medication is a combination of sofosbuvir and velpatasvir. This drug work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover
WHAT ARE THE USES OF SOFOSBUVIR 400 MG AND VELPATASVIR 100 MG TABLETS ?
Zydus Heptiza Sofosbuvir and Velpatasvir is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin).
SOFOSBUVIR VELPATASVIR COMMON SIDE EFFECTS :
Common SoviHep V side effects may include:
nausea, diarrhea; or
sleep problems (insomnia).
Call your doctor at once if you have:
weak or shallow breathing; or
low red blood cells-pale skin, weakness, rapid heart rate, trouble concentrating.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects.
What is DaciHep? DaciHep is an antiviral medicine that is used in combination with other medicines to treat hepatitis C in adults. The drug contains the active substance Daclatasvir that blocks the activity of a hepatitis C virus protein called "NS5A", which is essential for virus multiplication. By blocking this protein, the drug stops the hepatitis C virus multiplication. There are several genotypes of hepatitis C virus and it has been shown that Daclatasvir is effective against genotypes 1 through 4. How is DaciHep used ? Daclatasvir can only be obtained with a prescription and treatment should be initiated and monitored by a physician experienced in the treatment of patients with chronic hepatitis C. It is available as 30 mg and 60 mg tablets. The usual dose is 60 mg once a day. Daclatasvir should be used in combination with other chronic hepatitis C medications such as sofosbuvir, peginterferon alfa and ribavirin. The combination of medication to be used and the duration of treatment will depend on the hepatitis C virus genotype the patient is infected with and the type of liver disease he or she has, for example, if he has cirrhosis (liver sclerosis) or if the patient's liver is no longer functioning suitable. For more information, see the prospectus. How does DaciHep work? The active substance in DaciHep, daclatasvir, blocks the activity of a hepatitis C virus called "NS5A", which is essential for virus multiplication. Blocking this protein stops the hepatitis C virus multiplication. There are several genotypes of hepatitis C and Daclatasvir has been shown to be effective against genotypes 1 to 4. What benefit has Daclatasvir shown during the studies? In a major study involving 211 adults, Daclatasvir used in combination with sofosbuvir (with or without ribavirin) has been shown to be effective in eliminating hepatitis C virus from the blood. Patients in the study were infected with genotypes 1, 2 or 3 and all received treatment for 12 or 24 weeks. Most patients had not been previously treated for hepatitis C, Although some were infected with standard 1-drug resistant genotype (consisting of telaprevir or boceprevir - the so-called NS3 / 4A inhibitors - in combination with peginterferon alfa and ribavirin). Approximately 99% of patients with genotype 1 (125 out of 126), 96% of patients with genotype 2 (25 out of 26) and 89% of patients with genotype 3 (16 out of 18) Of the virus in the blood at 12 weeks after the end of the planned treatment. Additional studies involving patients with genotype 4 indicate that Daclatasvir is as effective against genotype 4 as against genotype 1. What are the associated risks? The most common side effects reported with Daclatasvir in combination with sofosbuvir, with or without ribavirin, Are exhaustion (fatigue), nausea and headache. For the full list of side effects reported with Daclatasvir, see the Package Leaflet. Daclatasvir is contraindicated with certain medicines that may reduce its effects. For more information on medicines that should not be taken with Daclatasvir, see the Package Leaflet.